Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O43167
UPID:
ZBT24_HUMAN
Alternative names:
Zinc finger protein 450
Alternative UPACC:
O43167; Q17RC6; Q5TED5; Q8N455
Background:
Zinc finger and BTB domain-containing protein 24, alternatively known as Zinc finger protein 450, plays a crucial role in the biological system, potentially involved in BMP2-induced transcription. This protein's unique structure and function underscore its significance in cellular processes.
Therapeutic significance:
Linked to Immunodeficiency-centromeric instability-facial anomalies syndrome 2, a rare disorder characterized by immunodeficiency and genomic instability, Zinc finger and BTB domain-containing protein 24's study could lead to novel therapeutic interventions for managing this complex syndrome.